Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study

MeSH terms

• Adult
• Antibodies, Monoclonal, Humanized / administration & dosage*
• Antibodies, Monoclonal, Humanized / adverse effects
• Drug Administration Schedule
• Female
• HLA-C Antigens / blood*
• HLA-C Antigens / immunology
• Humans
• Injections, Subcutaneous
• Male
• Middle Aged
• Prospective Studies
• Psoriasis / blood
• Psoriasis / diagnosis
• Psoriasis / drug therapy*
• Psoriasis / immunology
• Severity of Illness Index
• Treatment Outcome